人心肌营养素-1重组腺病毒载体的构建、纯化及表达

目的　构建人心肌营养素 1重组腺病毒载体 ,以期用于神经系统退行性疾病及损伤的在体研究。方法　构建穿梭质粒pDC3 16 huCT1和pDC3 16 eGFP ,CsCl梯度离心制备高纯度的病毒基因组质粒pBHloxdeltaE1,3Cre、pHG14 0。培养2 93细胞 ,CaCl2 法质粒共转染 2 93细胞构建并筛选腺病毒AdCMV huCT1和AdCMV eGFP。病毒原液转染 2 93细胞及NIH3T3细胞 ,PCR、RT PCR及免疫组化鉴定。CsCl梯度离心纯化病毒 ,空斑试验检测病毒滴度。纯化病毒注入大鼠颈脊髓 ,RT PCR及免疫组化检验AdCMA huCT的在体表达。结果　采用双质粒共转染 2 93细胞Cre loxP位点同源重组方法构建了E1和E3缺失的含MCMV启动子、外源基因和SV40PloyA的AdCMV huCT1和AdCMV eGFP载体。经过PCR、RT PCR和免疫组化证实腺病毒载体构建成功。病毒经过CsCl梯度离心纯化后 ,AdCMV huCT1滴度达到 3 .0× 10 1 0 pfu。RT PCR及免疫组化显示AdCMV huCT1在大鼠脊髓中特异性表达。结论　构建并纯化了体外及体内高效表达的AdCMV huCT1。     

endostatin基因重组腺病毒的构建及在人肺腺癌细胞的表达

目的 利用AdEasy系统构建鼠内皮抑素(ES)基因重组腺病毒Ad.ES,并观察其在人肺腺癌细胞SPCA-1的表达.方法 采用酶切、连接和转化等方法,将质粒pcDNA3.ES中的ES片段插入腺病毒穿梭质粒载体pAdTrack.CMV,构建重组腺病毒穿梭质粒载体pAdTrack.CMV.ES,经Pme Ⅰ酶切线性化后与含腺病毒基因骨架的质粒载体pAdEasy-1在细菌BJ5183内进行同源重组得到腺病毒质粒pAd.ES,重组腺病毒质粒经PacⅠ酶切后,转染人胚肾293细胞包装成腺病毒颗粒Ad.ES,将病毒上清反复感染293细胞获得高滴度病毒,应用氯化铯(CsCl)梯度离心的方法纯化病毒,利用AdEasy系统上的绿色荧光蛋白(GFP)标签测定重组腺病毒的功能滴度.用2 MOI重组腺病毒Ad.ES体外转导SPCA-1细胞48h,流式细胞仪检测GFP表达阳性率,ELISA法测定细胞培养上清液中ES的含量.结果 双酶切证实重组腺病毒穿梭载体pAdTrack.CMV.ES质粒构建正确,卡那霉素抗性筛选和Pac Ⅰ酶切鉴定证实腺病毒重组质粒构建成功.Pac Ⅰ酶切线性化的重组质粒导入293细胞3d,约20%的细胞表达GEP,回收病毒重复感染293细胞,CsCl梯度离心纯化最终获得约5.6×1010TU/mL滴度的重组病毒.Ad.ES体外转导SPCA-1细胞48h后,细胞GFP阳性率为93%,细胞培养上清液中ES的含量较Ad.GFP感染组和阴性对照组明显增加(P＜0.05).结论 应用新型腺病毒载体AdEasy系统可在短期内制备同时表达GFP和ES的重组腺病毒,Ad.ES体外感染人肺腺癌细胞SPCA-1可显著提高ES表达,为进一步研究抗血管生成治疗肺癌奠定了基础.     

应用AdMax载体系统构建SCL基因重组腺病毒表达载体

目的 用AdMax载体系统构建人SCL基因重组腺病毒载体,为研究SCL基因对ICC样细胞功能恢复奠定基础.方法 采用PCR方法从含人SCL基因质粒中扩增SCL基因,连接到腺病毒穿梭质粒的多克隆位点上,构建重组穿梭质粒pDC315-EGFP/SCL,在脂质体介导下与腺病毒辅助大质粒pBHGlox(delta)E1、3Cre共转染293细胞,包装产生复制缺陷型重组腺病毒pDC315-SCL经HEK293细胞扩增,纯化后测定病毒滴度.结果 PCR结果和Western blotting检测证实pDC315-SCL重组腺病毒载体构建成功,滴度达到1×1010 PFU/mL.结论 AdMax载体系统可成功构建pDC315-SCL重组腺病毒载体.     

HBV-TR重组腺病毒载体的构建

目的: 构建乙肝病毒靶向核糖核酸酶(HBV targeted ribonuclease, TR)基因的重组腺病毒载体. 方法: 将HBV-TR基因及其对照组基因分别克隆入质粒载体pDC316得到pDC316/TR等穿梭质粒,然后将所得的穿梭质粒和辅助质粒pBHGlox(delta)E1, 3Cre以磷酸钙法共转染HEK293细胞得到重组腺病毒Ad/TR及对照组重组病毒,并以空斑形成实验(Plaque Assay)测定病毒滴度. 结果: 成功构建了HBV-TR重组腺病毒载体Ad/TR及其对照组病毒并获得了高滴度的病毒颗粒. 结论: HBV-TR重组腺病毒载体成功构建.     

人canstatin基因重组腺病毒载体的构建及其病毒制备

目的:利用HEK293细胞内同源重组法构建带有绿色荧光蛋白报告基因的人血管能抑素(canstatin)重组腺病毒载体,扩增并纯化重组腺病毒颗粒.方法:PCR法扩增cansta-tin全长基因,克隆至pGEM-T载体,经酶切和测序证实后,亚克隆到穿梭质粒pAdS-CMV中,获得穿梭质粒pAdS-CMV/canstatin.用PasI酶单独酶切穿梭质粒pad5-CMV/canstatin和腺病毒E3区带有绿色荧光蛋白表达元件的腺病毒骨架载体,采用标准的磷酸钙方法共转染HEK293细胞.7～10 d后收获细胞裂解物,在HEK293细胞中扩增,病毒颗粒经氯化铯密度梯度离心纯化后,分光光度计检测重组病毒滴度.结果:测序证实pEGM-T/canstatin基因片段与GenBank公布的can-statin基因序列一致.重组腺病毒质粒转染293细胞后24 h观察到绿色荧光,病毒纯化后制备出高滴度重组腺病毒(病毒滴度为2.0×1015pt/L).结论:成功构建了表达canstatin基因的重组腺病毒载体并制备了重组腺病毒颗粒,为研究该基因在肿瘤治疗中的作用奠定了基础.     

骨形态发生蛋白-4基因重组腺病毒载体的构建

目的:通过Cre/LoxP位点特异性重组系统构建携带人骨形态发生蛋白-4基因的重组腺病毒载体(Ad.BMP4)。方法:根据GenBank获得BMP4的基因序列合成引物,经PCR扩增获得长度为1230bp的BMP4基因片断,经酶切、测序鉴定后,与腺病毒穿梭质粒pSuCMV连接,随后与5'缺陷型腺病毒右臂的质粒pBGHloxPΔE1E3通过脂质体Lipofectamine2000共转染至293细胞,获得重组腺病毒Ad.BMP4,并予以扩增、纯化、鉴定。结果:经酶切电泳和测序证明获得的BMP4基因片断序列、大小和方向正确,目的基因插入的位置、方向正确,经重组、扩增和纯化后获得病毒滴度为2.9×109pfu/ml的重组腺病毒Ad.BMP4,以PCR扩增和测序的方法证实了所构建病毒含有目的基因的片断,安全性检测证明所构建的腺病毒无野生性腺病毒的存在。结论:通过Cre/LoxP位点特异性重组系统构建了腺病毒Ad.BMP4。采用的腺病毒载体点特异性重组的方法极大地提高了包装成功率,且包装成功的病毒颗粒均为含有目的基因的重组病毒,从而保证了重组过程的快速和高效。     

基质金属蛋白酶组织抑制剂1基因重组腺病毒载体的构建

目的 为探讨基因治疗逆转或延缓椎间盘退变的可行性,构建及制备人基质金属蛋白酶组织抑制剂1 (tissue inhibitor of metalloproteinase 1,TIMP1) cDNA重组腺病毒载体.方法 以含TIMP1 cDNA序列的质粒为模板,通过PCR方法扩增TIMP1cDNA片段,将TIMP1 cDNA全长定向克隆到Ad5MaxTM腺病毒系统的穿梭质粒pDC316上,构建pDC316-TIMP1穿梭质粒;使用Ad5MaxTM腺病毒包装系统,脂质体介导的穿梭质粒及骨架质粒pBHGlox-E1,3Cre共转染HEK293细胞,同源重组构建含TIMP1 cDNA的重组腺病毒Ad5-TIMP1,通过PCR方法鉴定重组腺病毒Ad5-TIM P1的正确性.通过阴离子柱层析方法纯化重组腺病毒Ad5-TIMP1并测定重组腺病毒感染滴度.结果 经PCR及酶切方法证实pDC316-TIMP1穿梭质粒中存在630 bp大小左右的插入片段,与目的基因TIMP1的cDNA大小一致;经PCR鉴定证实TIMP1 cDNA重组腺病毒载体Ad5-TIMP1构建成功,病毒感染性滴度为1×1010 IU/mL.结论 成功构建TIMP1 cDNA重组腺病毒载体,为应用基因治疗方法逆转或延缓椎间盘退变的研究奠定实验基础.     

人生长终止特异性同源盒基因重组腺病毒载体的构建及鉴定

目的 生长终止特异性同源盒(growth arrest-specific homeobox,Gax)基因表达产物是核转录因子,主要存在于心血管系统中,对胚胎发育、细胞生长、分化和迁移等起基因调控作用,其表达异常与多种疾病相关.为深入研究Gax基因在临床疾病中的作用,文中构建表达了人Gax基因的重组腺病毒载体.方法 根据pEGFP-N1-Gax质粒的多克隆位点,用NheⅠ和Hind Ⅲ双酶切获得人Gax基因片段,连接至穿梭质粒pDC18-mCMV上,构建穿梭质粒pDC318-mCMV-Gax,然后与骨架质粒pPE3共转染293包装细胞,同源重组产生复制缺陷型重组腺病毒载体Ad5-Gax,反复感染293细胞扩增病毒后,氯化铯梯度离心纯化病毒,并测定病毒滴度.结果 穿梭质粒pDC318-mCMV-Gax经双酶切和测序证实构建成功;PCR鉴定人Gax基因重组腺病毒载体构建成功,病毒滴度为4.5×1010pfu/ml.结论 该研究成功构建了重组腺病毒载体Ad5-Gax,为进一步在体内外研究Gax基因参与多种疾病的发生发展提供了材料.     

靶向大鼠AT1-R基因的短发夹RNA重组腺病毒载体的构建及鉴定

目的利用AdMax腺病毒载体系统构建大鼠AT1-shRNA腺病毒载体并在293细胞中扩增制备重组病毒。方法自先期构建的pGenesil-1-AT1-shRNA真核表达载体中用RT-PCR法扩增出AT1-shRNA片段，将其克隆人PUC18质粒中。酶切构建好的pUC18-AT1-shRNA载体并克隆进入穿梭质粒pDC316中，将构建好的穿梭质粒pDC316AT1-shRNA载体和骨架病毒pBHGlox△1，3Cre共转染293细胞，包装成重组的病毒颗粒，荧光显微镜观察绿色荧光表达。结果经限制性内切酶、PCR检测和GFP表达证实成功地构建了携带AT1-shRNA的重组腺病毒载体并制备出高滴度重组病毒。结论成功地构建了携带AT1-shRNA片段的重组腺病毒载体，为进一步抗血压研究奠定了基础。     

携带凋亡素、内皮抑素双基因腺病毒载体的构建

目的构建携带有凋亡素(Apoptin、VP3)、内皮抑素(Endostatin)双基因的重组腺病毒载体,为其在肿瘤治疗的应用研究打下基础。方法将VP3基因和Endostatin基因克隆入腺病毒穿梭质粒pDC316中,将该穿梭质粒与腺病毒骨架质粒pBHGloxE1,3Cre共转染HEK293细胞,包装出重组腺病毒颗粒Ad-vp3-IRES-sEndo-his。其后挑选病毒空斑获取克隆进行小剂量扩增并提取病毒DNA进行PCR、RT-PCR检查以筛选和鉴定毒种,之后大剂量扩增所选得的病毒克隆并进行纯化、测定病毒的滴度。结果所得腺病毒经PCR、RT-PCR检测表明重组腺病毒Ad-vp3-IRES-sEndo-his包装成功。测定病毒50%组织培养感染剂量(TCID50)为5.7×109/ml,病毒颗粒滴度(VP)为1.9×1011/ml。结论成功构建携带凋亡素、内皮抑素双基因腺病毒载体并对其进行了大剂量扩增及提纯,达到了细胞及动物实验使用的标准。     

以AdMax载体系统构建携带HCV NS5B基因的重组腺病毒表达载体

目的构建表达丙型肝炎病毒(HCV)非结构基因NS5B的重组腺病毒表达载体,并对其相关指标进行鉴定,为进一步研究防止丙型肝炎感染的基因免疫和基因治疗奠定实验基础。方法应用基因工程技术将HCVNS5B基因定向克隆至穿梭质粒pDC316上,利用脂质体介导的方法将AdMax腺病毒包装系统的骨架质粒pBHGloxΔE1、3Cre和穿梭质粒pDC316-NS5B共转染293细胞,进行同源重组,产生重组腺病毒pAd-NS5B并进行鉴定、反复感染293细胞进行扩增,扩增后测定重组病毒滴度。结果重组病毒颗粒pAd-NS5B经双引物PCR、凝胶电泳证明插入片段与HCV非结构基因NS5B片段大小相符;经测序证明其插入序列与设计HCV NS5B基因序列完全一致,扩增后重组病毒滴度达到2.3×1013IU/L。结论成功构建了表达HCV NS5B基因的重组腺病毒载体。     

E型沙眼衣原体MOMP基因重组腺病毒的构建及免疫原性研究

目的:构建E型沙眼衣原体(Ct)主要外膜蛋白（MOMP）基因重组腺病毒,为沙眼衣原体腺病毒疫苗的研究奠定基础。方法: 根据Genebank中E型Ct MOMP基因序列设计引物,用高保真PCR方法从E型Ct基因组DNA中扩增得到MOMP基因片段,克隆至pcDNAII载体,测序后连接入腺病毒穿梭载体pDC316。穿梭载体pDC316 MOMP与含腺病毒基因组的辅助质粒PBHGlox△E1,3Cre共转染至HEK293细胞,在Cre loxP重组酶作用下进行重组,包装成重组腺病毒颗粒,用PCR和RT PCR方法进行鉴定。并用动物免疫试验检测重组腺病毒的免疫原性。结果:从E型Ct基因组DNA中扩增出约1.1?kb的特异MOMP基因片段,酶切鉴定及DNA序列测定证实穿梭载体pDC316 MOMP构建正确。穿梭载体pDC316 MOMP与含腺病毒基因组的辅助质粒PBHGlox△E1,3Cre共转染至293细胞,出现明显细胞病变效应。收集重组腺病毒,PCR法证实重组腺病毒含有MOMP基因,RT PCR证实重组腺病毒在293细胞能表达MOMP基因。重组腺病毒免疫小鼠可诱导特异性抗体产生,证明重组腺病毒具有良好免疫原性。结论:成功构建了E型沙眼衣原体MOMP基因重组腺病毒,该重组腺病毒可诱导小鼠产生特异性抗体。     

狨猴血清中重组人5型腺病毒中和抗体滴度的测定

目的构建表达荧光素酶与绿色荧光蛋白报告基因的重组人5型腺病毒rAd5/Luc/GFP,检测血清中和抗体最佳实验方法, 分析小型灵长类动物普通棉耳狨猴体内腺病毒5型中和抗体水平,为评价腺病毒载体疫苗提供实验动物基础数据。方法利用 ADMax包装系统,首先构建穿梭质粒pDC315-Luc-GFP,将所得的穿梭质粒和骨架质粒pBHGloxΔE1,3Cre共转染293A细胞, 进行重组人5型腺病毒（rAd5/Luc/GFP）的包装。通过3次空斑形成实验筛选出单克隆重组腺病毒,并在大量扩增单克隆腺病毒 后用CsCl密度梯度离心法进行浓缩纯化。采用TCID50法测定纯化后病毒滴度,并挑选进行中和实验的最优病毒滴度。将合 适病毒滴度的rAd5/Luc/GFP与狨猴血清混合预孵育后感染293A细胞,分别采用化学发光法及流式细胞术,对14只普通棉耳狨 猴血清中腺病毒5型中和抗体进行检测。结果PCR、酶切和测序结果均表明穿梭质粒pDC315-Luc-GFP构建成功;GFP检测 结果证明重组人5型腺病毒rAd5/Luc/GFP包装扩增成功,病毒滴度可达6.9×1011.5 PFU/mL。两种不同方法检测检测14只狨猴 的中和抗体结果一致性较好（P<0.05,Kappa=0.811）,化学发光法或流式细胞术检测阳性狨猴比率分别为28.6%（4/14）或21.4% （3/14）,化学发光法检测得其中2只狨猴中和抗体滴度为1/16,另2只为1/32,而流式细胞术检测得滴度均为1/16。结论化学发 光法是一种快速,准确,适用于多物种的方法,其灵敏度略高于以GFP为报告基因的流式细胞术（7.2%）。普通棉耳狨猴体内 Ad5血清阳性率较低,有望应用基于此型或其他型别腺病毒作为载体进行基因治疗和基因疫苗研究。     

Betatrophin重组腺病毒过表达载体的构建

［摘要］目的: 应用基因同源重组技术,构建及鉴定携带小鼠betatrophin基因Gm6484(NM_001080940)的复制缺陷型重组腺病毒载体,为进一步研究betatrophin的功能奠定基础。方法: 根据基因库中登录的小鼠betatrophin基因Gm6484(NM_001080940)序列,经化学合成得到含BamHⅠ/ AgeⅠ酶切位点的小鼠betatrophin基因全长cDNA质粒,将其酶切后插入到带有增强型绿色荧光蛋白（enhanced green fluorescent protein,EGFP）基因的GV314载体CMV MCS 3FLAG SV40 EGFP中,得到重组病毒穿梭质粒pGV314 betatrophin;经BamHⅠ/ AgeⅠ双酶切后,与线性化的pDC315病毒基因组质粒体外同源重组,构建含有目的基因的腺病毒载体Ad betatrophin,酶切线性化重组腺病毒质粒后转染HEK293T细胞包装成重组病毒颗粒,经在HEK293T细胞反复扩增数代后,利用聚合酶链式反应（PCR）、蛋白质印迹法及测序鉴定重组的腺病毒。结果： 阳性克隆质粒Ad betatrophin在HEK293T细胞中成功包装出重组病毒,经PCR、蛋白质印迹及测序检测表明重组腺病毒包装成功。结论： 成功构建了携带小鼠betatrophin基因的复制缺陷型重组腺病毒过表达载体。     

Construction of a bicistronic recombinant adenoviral vector for human interleukin-10 and enhanced green fluorescent protein expression in bone marrow mesenchymal stem cells

Background  Human interleukin-10 (hIL-10) is a cytokine synthesis inhibitory factor, which is involved in various immune responses. The purpose of this study was to construct an adenoviral vector carrying the hIL-10 gene for expression of biologically active hIL-10 in rat bone marrow mesenchymal stem cells (rMSCs).

Methods  A pSNAV2.0-hIL10 plasmid was used as a template to obtain a hIL-10 cDNA fragment that was subcloned by restriction enzyme digestion and ligation into a pDC316-IRES-EGFP-lacZ alpha plasmid carrying an enhanced green fluorescent protein (EGFP) marker gene. The pDC316-hIL-10-IRES-EGFP plasmid was linearized by PmeI digestion and used to transfect HEK293 packaging cells using the adenovirus packaging system AdMax. Virus particles were amplified by repeatedly infecting HEK293 cells with the seed virus and then purified by ion exchange. After the number of virus particles and titer was determined, rMSCs were infected with the adenoviral vector. The infection rate was determined by fluorescence microscopy and flow cytometry, and hIL-10 protein expression in rMSCs was measured by Western blotting.

Results  The virus particle concentration, OD260/280 value and virus titer of the amplified and purified recombinant adenovirus were 3.2×10¹¹ VP/ml, approximately 2.0, and 1.1×10¹⁰ TCID50/ml, respectively. Bright green fluorescence was observed by fluorescence microscopy and flow cytometry in the recombinant adenovirus-infected rMSCs. GFP expression was considered the multiplicity of infection (MOI) and was time-dependent. The infection rate was 92.9% at 100 MOI.

Conclusions  A bicistronic recombinant adenoviral vector for hIL-10 and EGFP gene expression were successfully constructed. The infection rate of rMSCs by the adenovirus was high (92.9% at 100 MOI) and the target gene hIL-10 was highly expressed in cells. The present study provides an experimental basis for further research of immunosuppressive therapy using hIL-10. The expression level of hIL-10 protein as detected by Western blotting was also MOI- and time-dependent.

     

负载hTERT调控相关miR-138复制缺陷型腺病毒的包装及鉴定

目的 包装负载人端粒酶逆转录酶(hTERT)调控相关miR-138前体全长cDNA(pre-miR-138)的复制缺陷型腺病毒载体(Ad-miR138).方法 pre-miR-138全基因合成后插入腺病毒穿梭质粒(pDC315-miR138),与腺病毒包装质粒pBHGloxDeltaE1、3Cre共转染人胚肾293细胞...     

Construction and identification of recombinant adenovirus-mediated gene transfer system for rat vascular endothelial growth factor

Objective To construct the recombinant adenovirus vector carrying rat vascular endothelial growth factor(VEGF), as preparation for genetic transfection that follows. Methods Rat VEGF was obtained by using RT-PCR amplification and then cloned into the shutter plasmid pDC316. Subsequently, this newly constructed plasmid pDC316-VEGF, after identification by nuclease digestion analysis and sequencing analysis, was transfected into human embryonic kidney cells HEK293 by Lipofectamine 2000 mediation, together with adenovirus-packaging plasmid pBHGE3. Based on the homologous recombination of the two plasmids within HEK293 cells, the recombinant adenovirus vector carrying VEGF and VDC316-VEGF was created. VDC316-VEGF was subsequently identified using PCR, purified using repeated plaque passages, proliferated using freezing and melting within HEK293 cells, and titrated using 50% Tissue Culture Infective Dose(TCID50) assay. ResultsThe newly constructed recombinant adenovirus was confirmed to carry rat VEGF based on PCR results, and its titration value determined based on TCID50 assay was 3×109 pfu/ml. ConclusionThe recombinant adenovirus carrying rat VEGF was successfully constructed. The newly constructed adenovirus can produce a sufficiently high titration value within HEK293 cells, providing a reliable tool for genetic transfection in further gene therapy researches.     

Construction of hepatocyte growth factor gene recombinant adenovirus vector and its expression in rat bone marrow mesenchymal stem cells

ObjectiveTo construct the adenoviral expression vector system containing human hepatocyte growth factor (hHGF) cDNA, and to further study the transduction efficiency and the expression of HGF in mesenchymal stem cells (MSCs). MethodsThe HGF cDNA was amplificated from the expression plasmid pCMV-HGF, and was subcloned into the adenovirus shuttle plasmid pDC316-IRES-EGFP vector containing a green fluorescence protein (GFP) reporter gene. Virus Ad-HGF was produced by homologous recombination in HEK293 package cells. Bone marrow derived MSCs were harvested and cultured, and then were transduced with Ad-HGF. The efficiency of Ad-HGF transduction was assessed by FACS analysis using GFP gene expression. And HGF/MSCs were generated. The HGF concentrations in supernatants of HGF/MSCs were determined by ELISA using anti-human HGF monoclonal antibody. Results The recombinant, named pDC316-HGF-IRES-eGFP, was digested with restriction enzyme, and the DNA sequencing of HGF was identical to the report in Genebank and did not reveal any mutation. GFP expression could be observed on the second day after packing of the linearized pAd-HGF in HEK293 cells and 7.15×1010pfu/ml titer of Ad-HGF was obtained. Forty-eight hours after transduction, 96.89% of HGF/MSCs were GFP positive. Peak concentration levels of hHGF(103ng/mL) in the cultured supernatants were detected on day 2 post-transduction, and the adenovirus-mediated expression of HGF by MSCs was maintained for at least 2 weeks in vivo. ConclusionOur data demonstrated that the adenovirus expression'vector system pDC316-HGF-IRES-EGFP has been constructed successfully, and their effective expressions also have been obtained in MSCs. This will provide material basis for the next study on liver regeneration after small-for-size liver transplantation.